MiniMed Group (MMED) vs Insulet (PODD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
Insulet is the larger company by market cap ($9.32 billion vs $5.38 billion), about 1.7 times the size. On valuation, Insulet trades at a lower forward P/E (17.4x vs 30.0x for MiniMed Group). Insulet converts more of its revenue into profit, with a net margin of 9.1% versus -10.7%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MMED | PODD |
|---|---|---|
| Share price | $19.11 | $134.36 |
| Market cap | $5.38B | $9.32B |
| 1-day change | -2.70% | -0.27% |
| YTD return | — | -52.73% |
| 1-year return | — | -57.14% |
| 5-year return | — | -55.29% |
| P/E ratio (TTM) | — | 25.16 |
| Forward P/E | 29.99 | 17.38 |
| EPS (TTM) | $-1.53 | $5.34 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $3.10B | $2.71B |
| Revenue growth (YoY) | +14.25% | +30.73% |
| Net income (latest FY) | $-333.00M | $247.10M |
| Gross margin | 54.16% | 71.63% |
| Operating margin | -6.13% | 17.50% |
| Net margin | -10.74% | 9.12% |
| 52-week high | $24.43 | $354.88 |
| 52-week low | $10.65 | $126.40 |
| Distance from 52-week high | -21.78% | -62.14% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +29.20% | +27.24% |
| Average volume | 2.35M | 1.69M |
| Shares outstanding | 281.35M | 69.35M |
| Employees | 8,000 | 5,400 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Insulet is more profitable, keeping 9.1 cents of every revenue dollar as net income versus -10.7 cents for MiniMed Group.
- Insulet grew revenue faster in its latest fiscal year (+30.73% vs +14.25%).
About MiniMed Group
MMED stock →MiniMed Group, Inc. operates as a medical technology company that develops, manufactures, and markets medical equipment for the management of diabetes.
Health Care · Medical/Dental Instruments · 8,000 employees
About Insulet
PODD stock →Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System.
Health Care · Medical/Dental Instruments · 5,400 employees
MMED vs PODD FAQ
Which is bigger, MiniMed Group or Insulet?
Insulet (PODD) is larger, with a market capitalization of $9.32B compared with $5.38B for MiniMed Group (MMED).
Are MiniMed Group and Insulet in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.